# US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump

> **Newsylist Open Intelligence Dossier** · First detected: 2026-11-21 01:29 UTC · Category: Business · Sources: 5 · Current Velocity: 13.98

## Intelligence Brief
&quot;US FDA declines to approve Capricor&#039;s Duchenne treatment citing unreliable trial data; shares slump&quot; developed substantial multi-source reporting across the Business sector, tracked across 5 distinct newsrooms by Newsylist.


Key reporting was led by TradingView, Bloomberg.com, Yahoo Finance and STAT. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for US FDA declines to approve Capricor's Duchenne treatment citing unreliable ?
Coverage spiked when 5 independent newsrooms published 5 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| TradingView | Key facts: FDA Extends Deramiocel Review; Capricor Reports Q3 Loss | 2026-11-20 23:42 | [Source Link](https://news.google.com/rss/articles/CBMixAFBVV95cUxPeXhSNWF4OWQ4TmFfUUlORG9vcHZ5N093XzJOdFFlZ0xrVlRId1VxbmJqTUM5N2ZENUdob2tGb0YydHJ0bzc3TkJyVzhpcWNPWmFUMWF5cnNubkQxVDl6cnIzVUEtRGNPNGxlX2Vkb0Y5TXUtNFZjckZ3N2c0VjNXYjcwdERIbFozcExsOFBhQVZkVkdHSG1oVkxTWGplbmxnZnY4eTgtam9BVzVFbE0xV3lVSk95NmJjZE5GV05WWkI3QWVO?oc=5) |
| Bloomberg.com | Capricor Gets Second FDA Rejection for Muscular Dystrophy Drug | 2026-11-20 23:42 | [Source Link](https://news.google.com/rss/articles/CBMixwFBVV95cUxQcFUzTkZXZnZQejZMU0RMOUdxQk01UXE1VExYYl9mcmFZZldSVWtNemJkNXRIazV2WkVVaWMtSlFBS0hOLTRkaGpHYnVyT2x0TVAwdnNIX0RPWE9TSnN0WDNjZ2NCXzNkSGM1Qm9ES0J2Z1ZsTFFoVjlzcUxiLWh6UGwtYWdqU1BtUW8zUGxOT1JLeWE1a1FQcXhJWG5DREdaaUpFX1hQNnNIUVJWamZ6c2F0YVlnQ3Q5TktXMExfeEV2TDViaEIw?oc=5) |
| Yahoo Finance | CAPR Stock Gains Ahead Of Weekend FDA Deramiocel Decision After Rough Week | 2026-11-20 23:42 | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxPT0E4em1DaVh6YUY5OU1Pb2o2elM5Mk5pTV9yNURwNlhsNkwxdGt3c3RYc0tucjByZnN2djZCc0k4b2hudTV5NktFcFI4STl5a3otNW5heXdhckNVSnlEaExDRTl6Z0hOOGZhTHljamFINnJuMGpfT2NTaEluaElQNkNCMXFDSkVlRDBubk56a3BWVjA3V0E?oc=5) |
| STAT | FDA rejects Capricor Therapeutics' Duchenne therapy, a decision that was a long time coming | 2026-11-20 23:42 | [Source Link](https://news.google.com/rss/articles/CBMif0FVX3lxTE9Nakdta19TM0VQMjFkMU5pcHJVajVsY2hsRDdlb3RkbEFSYm1TaERxR0RMSHdjbXhvNF9SUDhwZUxGM2VPdGxKSnZ3VjhKa29Hc3dEenZPSF8tU0RBZzBnaW1KWU5SR1R0Z3BJZ0luaEFGV3dMUi1KanpUcVkxbEE?oc=5) |
| Reuters | US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump | 2026-11-20 23:42 | [Source Link](https://news.google.com/rss/articles/CBMixgFBVV95cUxNUUJ5QjBndGJPNTFwMHRqRzZVNHRqd0JpaW1oc2UxeGd0RXpYNDNWQlE2Yl9vLVBfbUxZS3ZqeG1iTnh3Um1vZXJRWU5aenBiaFlYRmRBVy00eFpYRVJFNHN0NTk2TVdWOXNfbHZKckxpRi05WDNJM2VaLWRjR1l0c3JrYkYyZEU0UFItS2NQR19Pb1cwWG1BNW43Y19mZE9EajUwZHA4RUJTOVFoOWdnbG5tT1pzdDhvVlI3MEZlcU50YWd0a2c?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-11-21/us-fda-declines-to-approve-capricor-s-duchenne-treatment-citing-unreliable*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*
